The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03037931




Registration number
NCT03037931
Ethics application status
Date submitted
25/01/2017
Date registered
31/01/2017
Date last updated
10/05/2019

Titles & IDs
Public title
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency
Secondary ID [1] 0 0
1VIT15043
Universal Trial Number (UTN)
Trial acronym
HEART-FID
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure 0 0
Iron-deficiency 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases
Blood 0 0 0 0
Anaemia
Diet and Nutrition 0 0 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ferric carboxymaltose
Treatment: Drugs - Placebos

Active Comparator: Ferric Carboxymaltose - Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by iron indices

Placebo Comparator: Placebos - Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.


Treatment: Drugs: Ferric carboxymaltose
Intravenous Iron

Treatment: Drugs: Placebos
Normal Saline Solution

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Death
Timepoint [1] 0 0
1 year
Primary outcome [2] 0 0
Incidence of hospitalization for heart failure
Timepoint [2] 0 0
1 year
Primary outcome [3] 0 0
Change in 6MWT distance
Timepoint [3] 0 0
6 months

Eligibility
Key inclusion criteria
1. Adult (=18 years of age) able to provide informed consent.

2. Stable heart failure (NYHA II-IV) on maximally-tolerated background therapy (as
determined by the site Principle Investigator) for at least 2 weeks prior to
randomization.

3. Able and willing to perform a 6MWT at the time of randomization.

4. Reduced left ventricular ejection fraction. Assessment must be performed at least 12
weeks after major cardiac surgical intervention including coronary artery bypass graft
(CABG), valvular repair/replacement, or cardiac resynchronization therapy (CRT) device
implantation.

a. Left ventricular ejection fraction = 40% obtained during the screening visit OR
either of the following i. Historical value of ejection fraction = 40% within 24
months of screening visit ii. Historical value of ejection fraction = 30% within 36
months of screening visit

5. Hemoglobin >9.0 g/dL and < 13.5 g/dL (females) or <15.0 g/dL (males) within 28 days of
randomization.

6. Serum ferritin <100 ng/mL or 100 to 300 ng/mL with TSAT <20%.Patients with screening
ferritin <15 ng/mL must have documentation of an appropriate evaluation, as determined
by the Principle Investigator, within 3 months of screening and prior to
randomization.

7. Either documented hospitalization for heart failure within 12 months of enrollment or
elavated N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 90 days of
randomization. a. For patients in normal sinus rhythm: N-terminal-pro-brain
natriuretic peptide (NT- proBNP) > 600 pg/mL (or BNP >200 pg/mL) . b . For patients in
atrial fibrillation: NT-proBNP >1000 pg/mL (or BNP >400 pg/mL) .
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known hypersensitivity reaction to any component of FCM.

2. History of acquired iron overload, or the recent receipt (within 3 months) of
erythropoietin stimulating agent, IV iron therapy, or blood transfusion.

3. Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or
stroke within 30 days of enrollment.

4. Uncorrected severe aortic stenosis, severe valvular regurgitation, or left ventricular
outflow obstruction requiring intervention.

5. Current atrial fibrillation or atrial flutter with a mean ventricular response rate
>100 per minute (at rest).

6. Current or planned mechanical circulatory support or heart transplantation.

7. Hemodialysis or peritoneal dialysis (current or planned within the next 6 months).

8. Documented liver disease, or active hepatitis (i.e. alanine transaminase or aspartate
transaminase >3 times the upper limit of normal range).

9. Current or recent (within 3 years) malignancy with exception of basal cell carcinoma
or squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia.

10. Active gastrointestinal bleeding.

11. Female participant of child-bearing potential who is pregnant, lactating, or not
willing to use adequate contraceptive precautions during the study and for up to 5
days after the last scheduled dose of study medication.

12. Inability to return for follow up visits within the necessary windows

13. Concurrently in a study with investigational product.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,SydneyTAS
Recruitment hospital [1] 0 0
SWSLHD-Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [3] 0 0
Cairns Hospital - Cairns
Recruitment hospital [4] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [5] 0 0
Core Research Group - Milton
Recruitment hospital [6] 0 0
Gold Coast University Hospital - Southport
Recruitment hospital [7] 0 0
The Queen Elizabeth Hospital - Adelaide
Recruitment hospital [8] 0 0
SA Heart - Ashford
Recruitment hospital [9] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [10] 0 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [11] 0 0
Heart Lung Clinic - Darlinghurst
Recruitment hospital [12] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [13] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
1871 - Liverpool
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
4870 - Cairns
Recruitment postcode(s) [4] 0 0
4032 - Chermside
Recruitment postcode(s) [5] 0 0
4064 - Milton
Recruitment postcode(s) [6] 0 0
4215 - Southport
Recruitment postcode(s) [7] 0 0
5011 - Adelaide
Recruitment postcode(s) [8] 0 0
5035 - Ashford
Recruitment postcode(s) [9] 0 0
5042 - Bedford Park
Recruitment postcode(s) [10] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [11] 0 0
- Darlinghurst
Recruitment postcode(s) [12] 0 0
7000 - Hobart
Recruitment postcode(s) [13] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
Arkansas
Country [5] 0 0
United States of America
State/province [5] 0 0
California
Country [6] 0 0
United States of America
State/province [6] 0 0
Colorado
Country [7] 0 0
United States of America
State/province [7] 0 0
Connecticut
Country [8] 0 0
United States of America
State/province [8] 0 0
Delaware
Country [9] 0 0
United States of America
State/province [9] 0 0
Florida
Country [10] 0 0
United States of America
State/province [10] 0 0
Georgia
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Indiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Mississippi
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
Nevada
Country [23] 0 0
United States of America
State/province [23] 0 0
New Jersey
Country [24] 0 0
United States of America
State/province [24] 0 0
New York
Country [25] 0 0
United States of America
State/province [25] 0 0
North Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
North Dakota
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oklahoma
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
South Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
South Dakota
Country [32] 0 0
United States of America
State/province [32] 0 0
Tennessee
Country [33] 0 0
United States of America
State/province [33] 0 0
Texas
Country [34] 0 0
United States of America
State/province [34] 0 0
Utah
Country [35] 0 0
United States of America
State/province [35] 0 0
Vermont
Country [36] 0 0
United States of America
State/province [36] 0 0
Virginia
Country [37] 0 0
United States of America
State/province [37] 0 0
Washington
Country [38] 0 0
United States of America
State/province [38] 0 0
Wisconsin
Country [39] 0 0
Canada
State/province [39] 0 0
Alberta
Country [40] 0 0
Canada
State/province [40] 0 0
British Columbia
Country [41] 0 0
Canada
State/province [41] 0 0
New Brunswick
Country [42] 0 0
Canada
State/province [42] 0 0
Newfoundland and Labrador
Country [43] 0 0
Canada
State/province [43] 0 0
Nova Scotia
Country [44] 0 0
Canada
State/province [44] 0 0
Ontario
Country [45] 0 0
Canada
State/province [45] 0 0
Quebec
Country [46] 0 0
Canada
State/province [46] 0 0
Saskatchewan
Country [47] 0 0
New Zealand
State/province [47] 0 0
Wellington
Country [48] 0 0
New Zealand
State/province [48] 0 0
Auckland
Country [49] 0 0
New Zealand
State/province [49] 0 0
Christchurch
Country [50] 0 0
New Zealand
State/province [50] 0 0
Dunedin
Country [51] 0 0
New Zealand
State/province [51] 0 0
Hastings
Country [52] 0 0
New Zealand
State/province [52] 0 0
Lower Hutt
Country [53] 0 0
New Zealand
State/province [53] 0 0
Nelson
Country [54] 0 0
New Zealand
State/province [54] 0 0
New Plymouth
Country [55] 0 0
New Zealand
State/province [55] 0 0
Tauranga

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
American Regent, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Duke Clinical Research Institute
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to determine the efficacy and safety of iron therapy
using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of
participants in heart failure with iron deficiency and with a reduced ejection fraction.
Trial website
https://clinicaltrials.gov/show/NCT03037931
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Adrian F Hernandez, MD
Address 0 0
Duke Clinical Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
James Bambrick
Address 0 0
Country 0 0
Phone 0 0
631-772-3518
Fax 0 0
Email 0 0
HEART-FID@luitpold.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03037931